LeMaitre Vascular, Inc.

As of June 30, 2026, LeMaitre Vascular, Inc. carries a market capitalization of 2.19B, placing it among publicly traded companies globally. Its enterprise value stands at 2.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

LeMaitre Vascular, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, LeMaitre Vascular, Inc. has 22.86M shares outstanding.

As of June 30, 2026, LeMaitre Vascular, Inc. trades at a trailing price-to-earnings ratio of 33.25. The price-to-sales ratio is 8.32, and the price-to-book ratio stands at 5.22.

As of June 30, 2026, LeMaitre Vascular, Inc. trades at an EV/EBITDA multiple of 22.87 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.97 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. LeMaitre Vascular, Inc. trades at an EV/FCF ratio of 25.79, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.01B versus a market cap of 2.19B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, LeMaitre Vascular, Inc. maintains a current ratio of 16.31, meaning it holds 16.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 45.26, indicating elevated leverage, while an interest coverage ratio of 16.90 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, LeMaitre Vascular, Inc. posted a return on equity (ROE) of 16.77, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.14 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.78, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.03, useful for judging operating efficiency across full business cycles. The company generates approximately 399,287.94 in revenue per employee across its workforce of 657.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.23 indicates how many times LeMaitre Vascular, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, LeMaitre Vascular, Inc. recorded 19.06M in income tax expense. That works out to an effective tax rate of 22.50, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 84.73M, leaving 65.67M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on November 4, 2026, LeMaitre Vascular, Inc.'s stock has gained approximately 0.76% over the past 52 weeks. The 50-day moving average sits at 81.38, while the 200-day moving average is 94.41.

Over the twelve months ended June 30, 2026, LeMaitre Vascular, Inc. generated 262.43M in revenue and converted that into 65.67M in net income, yielding earnings per share of 2.77. EBITDA reached 87.82M, while operating income came in at 77.32M.

As of June 30, 2026, LeMaitre Vascular, Inc. holds 376.24M in cash and equivalents against 190.25M in total debt, resulting in a net debt position of 142.47M. Total book value stands at 420.34M, with working capital of 458.36M providing operational flexibility.

LeMaitre Vascular, Inc. produced 82.98M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9.15M in capital expenditures, free cash flow totaled 73.83M - equivalent to 3.24 per share.

Over the twelve months ended June 30, 2026, LeMaitre Vascular, Inc. posted a gross margin of 72.90, reflecting its pricing power and cost economics. The operating margin of 29.46 and net profit margin of 25.02 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, LeMaitre Vascular, Inc. paid dividends of 0.90 per share. The dividend payout ratio of 31.21 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.24, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.67, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to LeMaitre Vascular, Inc. shareholders.

As of June 30, 2026, LeMaitre Vascular, Inc. has an Altman Z-Score of 8.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.